Risk factor
Very poor trading liquidity
Profitability factor
Favourable analyst view
About
Atrys Health, S.A., a biomedical enterprise founded in 2007 and based in Madrid, Spain, specializes in providing a range of diagnostic services and medical treatments. Its diagnostic portfolio encompasses areas like pathology, hematology, molecular pathology, and genetics, supplemented by offerings such as diagnostic second opinions, a comprehensive test directory, and support for clinical trials and research & development. The company effectively utilizes telemedicine to deliver its expertise in medical specialties including radiology, cardiology, ophthalmology, and dermatology. Furthermore, Atrys Health administers radiotherapy and is engaged in the development of innovative therapeutic approaches and diagnostic instruments. The organization operated as Althia Health, S.L. before rebranding to Atrys Health, S.A. in May 2016.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB
Target Price
The average target price of ATRY.MC is 5.03 and suggests 96.5% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i